Effect of thiazolidinediones on dislipidemia in patients with metabolic syndrome depending on the gene PPAR-gamma rs1801282 polymorphism
Background. To evaluate the effect of thiazolidinediones on lipid spectrum of blood in patients with metabolic syndrome depending on gene polymorphism rs1801282. Materials and methods. The study included 109 patients with newly diagnosed metabolic syndrome. All subjects in the study underwent general clinical, laboratory methods, presence of polymorphism rs1801282 of the PPAR-gamma gene was also determined. All patients were recommended to keep a diet, increase physical activity and receiving pioglitazone 30 mg per day for the period of 3 months. Results.During therapy with pioglitazone it was noted that the degree of reduction of triglycerides was more pronounced in patients with IGT carrying rs1801282 -1.2 (-1.7; -1.1) versus -0.2 (-0.4; 0.0) in patients with wild genotype (p < 0.001) as well as in patients with type 2 diabetes, carries of polymorphic allele -1.3 (-1.6; -1.2) versus -0.2 (-0.3; 0.0) in patients with wild genotype (p < 0.001). Conclusion. As a result of administering pioglitazone, an improvement in the lipid spectrum of the examined patients was noted. The maximum degree of reduction of triglycerides was observed in patients carrying rs1801282 polymorphic allele compared with the wild genotype.